What is the dose of Mounjaro (tirzepatide)?

From the Guidelines

Mounjaro (tirzepatide) should be administered at a total dose range of 15 mg weekly for maximum effect, as indicated in the most recent study published in 2025 1. The dose of Mounjaro is administered subcutaneously, with a total dose range of 15 mg weekly for maximum effect.

• The administration route is subcutaneous (SC)
• The pharmacokinetics of Mounjaro include an area under the curve (AUC) of 43,459 ng.h after a single dose, with a bioavailability of 1250 ng.ml and a volume of distribution of 80 l.
• The fraction bound to plasma protein is 10.3%, with an elimination half-life of 5 days, and the major elimination route is metabolized. According to the study published in Anaesthesia in 2025 1, Mounjaro has a once-weekly dosing regimen, which is convenient for patients and can improve adherence to treatment.
• The study also notes that no dose change is necessary for Mounjaro, making it a straightforward treatment option for patients. It is essential to consider the properties of GLP-1RA and GIP when administering Mounjaro, as it works by activating both GLP-1 and GIP receptors to regulate blood sugar and provide weight loss benefits.
• As indicated in the study 1, Mounjaro has a unique mechanism of action that can provide effective glycemic control and significant weight loss benefits in patients with type 2 diabetes.

From the FDA Drug Label

The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose. The maximum dosage of MOUNJARO is 15 mg injected subcutaneously once weekly.

The dose of MOUNJARO is as follows:

• Starting dose: 2.5 mg injected subcutaneously once weekly
• Dose escalation: increase to 5 mg after 4 weeks, and then in 2.5 mg increments every 4 weeks as needed
• Maximum dose: 15 mg injected subcutaneously once weekly 2

From the Research

Dose of Mounjaro

• The dose of Mounjaro (tirzepatide) varies, with studies indicating doses of 5 mg, 10 mg, and 15 mg once weekly 3, 4.
• In the SURPASS-2 clinical trial, participants received tirzepatide at doses of 5 mg, 10 mg, or 15 mg, with significant reductions in glycated hemoglobin and body weight observed at all doses 3.
• The maximum tolerated dose of tirzepatide used in a phase 3b clinical trial for obesity management was 10 mg or 15 mg subcutaneously once weekly 5.
• The efficacy and safety of tirzepatide at these doses have been demonstrated in several clinical trials, with a low risk of hypoglycemia and a generally similar safety profile to the GLP-1 receptor agonist class 3, 4.

Administration

• Mounjaro is administered subcutaneously once weekly 3, 4, 5.
• It is available as single-dose prefilled pens and single-dose vials 6.

Clinical Trials

• The SURPASS clinical trial program assessed the efficacy and safety of once-weekly subcutaneously injected tirzepatide (5,10, and 15 mg) in adults with type 2 diabetes 4.
• The SURMOUNT-5 clinical trial compared the efficacy and safety of tirzepatide with semaglutide in adults with obesity but without type 2 diabetes 5.